b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29161237</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>06</Month>\n            <Day>24</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>06</Month>\n            <Day>24</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Electronic">1937-1578</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>13</Volume>\n                    <Issue>3</Issue>\n                    <PubDate>\n                        <MedlineDate>2019 Summer</MedlineDate>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Retinal cases &amp; brief reports</Title>\n                <ISOAbbreviation>Retin Cases Brief Rep</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>BILATERAL VISUAL FIELD DEFECTS IN A PATIENT TREATED WITH THE MEK AND BRAF INHIBITORS TRAMETINIB AND DABRAFENIB FOR MELANOMA OF UNKNOWN ORIGIN.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>215-219</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1097/ICB.0000000000000585</ELocationID>\n            <Abstract>\n                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Although the introduction of BRAF and MEK inhibitors has greatly enhanced treatment possibilities in advanced BRAFV600-mutated melanoma, class-related toxicities are rather frequent and often involve the eye. Ophthalmologic side effects most commonly include central/diffuse serous retinopathy and retinal vein occlusion. Affection of the optic nerve head however has not been described clinically.</AbstractText>\n                <AbstractText Label="CASE REPORT" NlmCategory="METHODS">A 29-year-old man presented in our eye clinic with bilateral blurred vision. Seventeen days earlier, he had been started on trametinib and dabrafenib combination therapy for metastasized melanoma of unknown origin. Visual field testing revealed diffuse bilateral defects, which regressed spontaneously on pause of MEK and BRAF inhibitor treatment.</AbstractText>\n                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">In addition to the widely known class-related retinal toxicity, MEK and BRAF inhibitor-associated adverse events may also involve the optic nerve head, causing visual field defects probably regressing spontaneously after discontinuation of targeted oncologic therapy. In such cases, repeat brain imaging and exclusion of melanoma-associated retinopathy is recommended. Reinitiation of treatment and subsequent dose escalation seem to be feasible, but should be monitored by an ophthalmologist.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Siedlecki</LastName>\n                    <ForeName>Jakob</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Departments of Ophthalmology, and.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mackert</LastName>\n                    <ForeName>Marc</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Departments of Ophthalmology, and.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wolf</LastName>\n                    <ForeName>Armin</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Departments of Ophthalmology, and.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Berking</LastName>\n                    <ForeName>Carola</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Dermatology and Allergology, Ludwig-Maximilians-University, Munich, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Priglinger</LastName>\n                    <ForeName>Siegfried G</ForeName>\n                    <Initials>SG</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Departments of Ophthalmology, and.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Eibl-Lindner</LastName>\n                    <ForeName>Kirsten</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Departments of Ophthalmology, and.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D002363">Case Reports</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Retin Cases Brief Rep</MedlineTA>\n            <NlmUniqueID>101298744</NlmUniqueID>\n            <ISSNLinking>1935-1089</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D010091">Oximes</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011728">Pyridones</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011744">Pyrimidinones</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>33E86K87QN</RegistryNumber>\n                <NameOfSubstance UI="C560077">trametinib</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>QGP4HA4G1B</RegistryNumber>\n                <NameOfSubstance UI="C561627">dabrafenib</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010091" MajorTopicYN="N">Oximes</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011744" MajorTopicYN="N">Pyrimidinones</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014786" MajorTopicYN="N">Vision Disorders</DescriptorName>\n                <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014794" MajorTopicYN="N">Visual Fields</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2017</Year>\n                <Month>11</Month>\n                <Day>22</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>25</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2017</Year>\n                <Month>11</Month>\n                <Day>22</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29161237</ArticleId>\n            <ArticleId IdType="doi">10.1097/ICB.0000000000000585</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'